Профиль инвестора Sunstep | Тинькофф Инвестиции Пульс

Sarepta announces $500M common stock offering Sarepta Therapeutics announced that it is offering to sell, subject to market and other conditions, $500M in shares of its common stock in an underwritten public offering. Sarepta intends to use the net proceeds from the offering principally for the continuation of, and initiation of further, clinical trials, commercialization, manufacturing, business development activities, including the potential licensing or acquisition of complementary products, technologies and entities, and other general corporate purposes. Goldman Sachs, J.P. Morgan Securities, Morgan Stanley,and Credit Suisse Securities are acting as the underwriters of the proposed offering.